Brain-Penetrating CDK4/6 Inhibitors Aucentra Therapeutics’ Thiazole-Pyrimidine Compounds for Glioblastoma

Glioblastoma multiforme is the most aggressive primary brain tumour, with a median survival of only 15-23 months and a 5-year survival rate of approximately 4.6%. The failure of most targeted cancer therapies in glioblastoma can be traced to a single fundamental obstacle: the blood-brain barrier. Adelaide-based Aucentra Therapeutics has identified a class of thiazole–pyrimidine compounds designed specifically to cross the blood-brain barrier while inhibiting CDK4/6, a key driver of cell cycle progression in more than 80% of glioblastoma cases.

The Problem

CDK4 and CDK6 (cyclin-dependent kinases 4 and 6) are central regulators of the cell cycle’s G1-to-S-phase transition. The CDK4/6-Rb axis is deregulated in over 80% of glioblastoma multiforme cases, arising from deletion of the CDKN2A/B suppressor genes, amplification or overexpression of CDK4/6, or deletion and mutation of the retinoblastoma protein Rb. CDK4, p16INK4a, and Rb are independent predictors of poor survival in glioblastoma patients.

Three CDK4/6 inhibitors – palbociclib, ribociclib, and abemaciclib – have been approved by the US FDA for breast cancer and have undergone clinical trials in glioblastoma. However, outcomes with palbociclib in glioblastoma clinical trials have been disappointing and trials were terminated. The primary reason for this failure is the blood-brain barrier (BBB): a layer of tightly connected endothelial cells with ATP-binding cassette (ABC) transporters, particularly P-glycoprotein and BCRP, that actively pump many drugs out of the brain before they can accumulate to therapeutic concentrations.

Abemaciclib shows relatively better brain penetration than palbociclib, but its therapeutic potential in glioblastoma remains uncertain. The field urgently needs CDK4/6 inhibitors with both potent CDK4/6 inhibitory activity and demonstrated ability to cross the BBB at therapeutically relevant concentrations.

What This Invention Does

The patent describes a class of thiazole-pyrimidine compounds with the general structural formula I: a thiazole ring connected to a pyrimidine core through an NH linker, with substituents R1 and R2 on the thiazole ring and a (CH)3 chain leading to an additional N-containing heterocyclic element. These compounds are considered to inhibit CDK4 and/or CDK6 activity, blocking tumour cell proliferation by preventing progression through the G1/S cell cycle checkpoint.

Critically, the compounds in this class are designed to cross the blood-brain barrier, overcoming the primary pharmacokinetic obstacle that has prevented existing CDK4/6 inhibitors from being effective in glioblastoma. The design strategy addresses BBB penetration through molecular properties that reduce efflux by P-glycoprotein and BCRP, allowing the drugs to accumulate within the brain at concentrations sufficient to achieve therapeutic CDK4/6 inhibition in glioblastoma cells.

The disclosure covers use of these compounds in treating proliferative cell diseases and conditions of the CNS, with glioblastoma as the primary indication.

Key Features

Thiazole-pyrimidine scaffold. The general structure I defines a class of compounds sharing a thiazole-pyrimidine core connected through an NH linker, providing the structural framework for CDK4/6 inhibitory activity with modifiable R1 and R2 substituents.

CDK4/6 inhibition. The compounds are designed to inhibit CDK4 and/or CDK6, the kinases responsible for driving cell cycle entry in the majority of glioblastoma tumours, blocking the aberrant proliferation that characterises this disease.

Blood-brain barrier penetration. Unlike approved CDK4/6 inhibitors that are substantially excluded from the brain by active efflux transporters, the thiazole-pyrimidine compounds in this class are designed to cross the BBB, addressing the key pharmacokinetic failure mode of existing CDK4/6 inhibitors in glioblastoma.

CNS cancer focus. The therapeutic application is specifically directed to proliferative diseases of the CNS, including glioblastoma multiforme, recognising the unique pharmacokinetic requirements for CNS-targeted oncology drugs.

Who Is Behind It?

The applicant is Aucentra Therapeutics Pty Ltd, an Australian pharmaceutical company. The named inventor is Shudong Wang, a medicinal chemist with expertise in kinase inhibitor design. This divisional was filed on 26 February 2026, derived from parent application AU 2021268689, which claims priority from Australian Provisional Patent Application 2020901435 filed on 6 May 2020. Madderns Pty Ltd in Adelaide are the patent attorneys.

Why It Matters

Glioblastoma remains one of the most treatment-resistant cancers, with essentially unchanged survival statistics over the past two decades despite extensive clinical research. The failure of targeted therapies in the brain is almost invariably attributed to inadequate BBB penetration rather than lack of biological rationale. The CDK4/6-Rb pathway is one of the most compelling validated targets in glioblastoma, deregulated in the overwhelming majority of cases, but the inability of available CDK4/6 inhibitors to reach the brain at therapeutic concentrations has prevented this target from being exploited clinically.

A compound that combines potent CDK4/6 inhibitory activity with confirmed BBB penetration would address a genuine unmet medical need that existing approved drugs cannot. The Australian origin of this research reflects the strong research base at South Australian universities in targeted cancer drug discovery, with Aucentra Therapeutics translating academic medicinal chemistry into clinical candidates.

---

AU 2026201442 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.

Related Concepts

The blood-brain barrier is a selective permeability barrier formed by tightly connected endothelial cells that restricts the passage of most drugs from the bloodstream into the central nervous system. For glioblastoma – the most lethal primary brain tumour – this barrier is the dominant reason most targeted therapies fail despite strong biological rationale.

CDK4 and CDK6 are kinases that drive cells from the G1 phase into S phase of the cell cycle. Their inhibition has proven effective in breast cancer, and deregulation of the CDK4/6 pathway in over 80% of glioblastoma cases makes brain-penetrating CDK4/6 inhibitors a high-priority therapeutic goal.